Anti-mitochondrial antibodies as markers of disease activity in childhood-onset systemic lupus erythematosus: a longitudinal cohort study
Authors' conclusion
AMA-IgG emerges as a promising biomarker of disease activity in cSLE, and its increase is in alignment with elevated IFNα2 expression.
Study context
- Population
- Patients with childhood-onset SLE (cSLE)cSLE, sera at 2 timepoints (TPs)
- Participants
- 29 patients
- Exposure
- Active disease vs clinically quiescent disease
- Outcome
- Anti-mitochondrial antibodies (AMA) and disease activity
Methodological detailstwo timepoints (active vs quiescent disease), AMA IgG, IgM and IgA binding to human mitochondria assessed by flow cytometry; IFNα2 by single-molecule array
- Two timepoints (active vs quiescent disease)
- AMA IgG, IgM and IgA binding to human mitochondria assessed by flow cytometry; IFNα2 by single-molecule array
Main finding
As reported in the abstract
- AMA-IgG decreased between TP-1 and TP-2
- P = 0.0426
- AMA-IgG correlation with SLEDAI at TP-1
- ρ = 0.41, P = 0.026
- AMA-IgG correlation with anti-dsDNA at TP-1
- ρ = 0.66, P = 0.0001
- AMA-IgM oscillated according to disease activity
- P = 0.0065
- AMA-IgG correlation with IFNα2 during active disease
- ρ = 0.729, P < 0.0001
- AMA-IgM correlation with IFNα2 during active disease
- ρ = 0.631, P = 0.001
Observational data: associations, not effects.
Further findings
Disease activity and treatment at each timepoint
Median prednisone dose TP-1 0.43 mg/kg/day · TP-2 0.14 mg/kg/day
- Disease activity and treatment at each timepoint — Median age at diagnosis
- 14.9 ± 3.6 years
- Disease activity and treatment at each timepoint — Median interval between TP-1 and TP-2
- 6 ± 3.7 months
Original publication
Anti-mitochondrial antibodies as markers of disease activity in childhood-onset systemic lupus erythematosus: a longitudinal cohort study. Rheumatology (Oxford). Published 23 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →